These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15356067)

  • 1. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.
    Orio F; Palomba S; Cascella T; De Simone B; Di Biase S; Russo T; Labella D; Zullo F; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4588-93. PubMed ID: 15356067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.
    Orio F; Palomba S; Cascella T; De Simone B; Manguso F; Savastano S; Russo T; Tolino A; Zullo F; Lombardi G; Azziz R; Colao A
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6072-6. PubMed ID: 16118336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function.
    Arikan S; Akay H; Bahceci M; Tuzcu A; Gokalp D
    Fertil Steril; 2009 Feb; 91(2):450-5. PubMed ID: 18501898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.
    Carmina E; Orio F; Palomba S; Longo RA; Cascella T; Colao A; Lombardi G; Rini GB; Lobo RA
    Am J Med; 2006 Apr; 119(4):356.e1-6. PubMed ID: 16564785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
    Meyer C; McGrath BP; Teede HJ
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
    Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
    J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
    Pepene CE; Ilie IR; Marian I; Duncea I
    Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome.
    Vryonidou A; Papatheodorou A; Tavridou A; Terzi T; Loi V; Vatalas IA; Batakis N; Phenekos C; Dionyssiou-Asteriou A
    J Clin Endocrinol Metab; 2005 May; 90(5):2740-6. PubMed ID: 15741256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
    Pepene CE
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):119-25. PubMed ID: 21740456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin administration improves endothelial function in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Alexandraki K; Protogerou A; Piperi C; Papamichael C; Aessopos A; Lekakis J; Mavrikakis M
    Eur J Endocrinol; 2005 May; 152(5):749-56. PubMed ID: 15879361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.
    Kravariti M; Naka KK; Kalantaridou SN; Kazakos N; Katsouras CS; Makrigiannakis A; Paraskevaidis EA; Chrousos GP; Tsatsoulis A; Michalis LK
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5088-95. PubMed ID: 15985492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.
    Tarkun I; Arslan BC; Cantürk Z; Türemen E; Sahin T; Duman C
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5592-6. PubMed ID: 15531516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome.
    Abali R; Tasdemir N; Alpsoy S; Tasdemir UG; Guzel S; Yuksel MA; Temel Yuksel I; Yilmaz M
    Arch Gynecol Obstet; 2015 May; 291(5):1075-80. PubMed ID: 25280574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.
    Sorensen MB; Franks S; Robertson C; Pennell DJ; Collins P
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):655-9. PubMed ID: 17054469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
    Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
    Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of cardiovascular risk factors in polycystic ovary syndrome patients combined with subclinical hypothyroidism.
    Pei YJ; Wang AM; Zhao Y; Yan L; Li M; White RE; Han GC
    Gynecol Endocrinol; 2014 Aug; 30(8):553-6. PubMed ID: 24884959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome.
    Palomba S; Falbo A; Giallauria F; Russo T; Tolino A; Zullo F; Colao A; Orio F
    Diabetes Care; 2010 Feb; 33(2):246-51. PubMed ID: 19933994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between copper, homocysteine and early vascular disease in lean women with polycystic ovary syndrome.
    Celik C; Bastu E; Abali R; Alpsoy S; Guzel EC; Aydemir B; Yeh J
    Gynecol Endocrinol; 2013 May; 29(5):488-91. PubMed ID: 23480818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory and endothelial markers in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Alexandraki K; Piperi C; Protogerou A; Katsikis I; Paterakis T; Lekakis J; Panidis D
    Eur J Clin Invest; 2006 Oct; 36(10):691-7. PubMed ID: 16968464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.